brolucizumab   Click here for help

GtoPdb Ligand ID: 8713

Synonyms: Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Approved drug
brolucizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal [2].
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record.
Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 [1].

Following regulatory approval brolucizumab took its place as a wet age-related macular degeneraton therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years [4], brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2019), EMA (2020))
International Nonproprietary Names Click here for help
INN number INN
10053 brolucizumab
Synonyms Click here for help
Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 536
Reactome Drug Reactome logo R-ALL-9679482
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 252827371
Search PubMed clinical trials brolucizumab
Search PubMed titles brolucizumab
Search PubMed titles/abstracts brolucizumab